332 related articles for article (PubMed ID: 17111523)
1. The negotiation and development of a clinical trial agreement.
Finn PB
J Biolaw Bus; 2006; 9(2):21-7. PubMed ID: 17111523
[TBL] [Abstract][Full Text] [Related]
2. Sponsored research agreements, university and government licensing, and clinical trial agreements: special contractual and intellectual property rights considerations.
Somers JP
J Biolaw Bus; 2003; 6(4):5-13. PubMed ID: 15072054
[TBL] [Abstract][Full Text] [Related]
3. Academic medical centers' standards for clinical-trial agreements with industry.
Mello MM; Clarridge BR; Studdert DM
N Engl J Med; 2005 May; 352(21):2202-10. PubMed ID: 15917385
[TBL] [Abstract][Full Text] [Related]
4. Gag clauses in clinical-trial agreements.
Steinbrook R
N Engl J Med; 2005 May; 352(21):2160-2. PubMed ID: 15917381
[No Abstract] [Full Text] [Related]
5. Researchers' views of the acceptability of restrictive provisions in clinical trial agreements with industry sponsors.
Mello MM; Clarridge BR; Studdert DM
Account Res; 2005; 12(3):163-91. PubMed ID: 16634168
[TBL] [Abstract][Full Text] [Related]
6. Medical schools found to vary in their drug-testing standards.
Dean C
N Y Times Web; 2005 May; ():A24. PubMed ID: 15981393
[No Abstract] [Full Text] [Related]
7. A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors.
Schulman KA; Seils DM; Timbie JW; Sugarman J; Dame LA; Weinfurt KP; Mark DB; Califf RM
N Engl J Med; 2002 Oct; 347(17):1335-41. PubMed ID: 12397192
[TBL] [Abstract][Full Text] [Related]
8. Industry-sponsored clinical research: a broken system.
Angell M
JAMA; 2008 Sep; 300(9):1069-71. PubMed ID: 18768418
[No Abstract] [Full Text] [Related]
9. Negotiating clinical trial agreements: bridging the gap between research institutions and companies.
Porter PD; Longmire B; Abrol A
J Health Life Sci Law; 2009 Apr; 2(3):121-42. PubMed ID: 19485028
[No Abstract] [Full Text] [Related]
10. The report of the committee of inquiry on the case involving Dr. Nancy Olivieri: a fiduciary law perspective.
Litman M; Sheremeta L
Health Law Rev; 2002; 10(2):3-13. PubMed ID: 15739307
[No Abstract] [Full Text] [Related]
11. Trial results must be accessible. Clinical research data, a public asset.
Prescrire Int; 2000 Dec; 9(50):183. PubMed ID: 11475501
[No Abstract] [Full Text] [Related]
12. Medical-research ethics under the microscope: schools try to plot the fine line between commercial links and conflicts of interest.
Mangan KS
Chron High Educ; 2003 Jul; 49(46):A22-4. PubMed ID: 15287130
[No Abstract] [Full Text] [Related]
13. Medicine. Clinical trials and industry.
Baird P; Downie J; Thompson J
Science; 2002 Sep; 297(5590):2211. PubMed ID: 12351773
[No Abstract] [Full Text] [Related]
14. Association between pharmaceutical involvement and outcomes in breast cancer clinical trials.
Peppercorn J; Blood E; Winer E; Partridge A
Cancer; 2007 Apr; 109(7):1239-46. PubMed ID: 17326054
[TBL] [Abstract][Full Text] [Related]
15. University-industry relationships in dentistry: past, present, future.
Barnett ML
J Dent Educ; 2002 Oct; 66(10):1163-8. PubMed ID: 12449211
[No Abstract] [Full Text] [Related]
16. The future of clinical research.
Vaitukaitis JL
Clin Res; 1991 Apr; 39(2):145-56. PubMed ID: 2044346
[No Abstract] [Full Text] [Related]
17. Managing clinical grant costs.
Glass HE; Hollander K
Contemp Clin Trials; 2009 May; 30(3):221-6. PubMed ID: 19470309
[TBL] [Abstract][Full Text] [Related]
18. Conflict-of-interest policies.
Ratain MJ; Sheridan ME
N Engl J Med; 2001 Mar; 344(13):1018. PubMed ID: 11280317
[No Abstract] [Full Text] [Related]
19. Divided loyalties: trust in science is being eroded. How can we restore it?
New Sci; 2005 Feb 26-Mar 4; 185(2488):3. PubMed ID: 15839009
[No Abstract] [Full Text] [Related]
20. Gold in the ivory tower: equity rewards of outlicensing.
Edwards M; Murray F; Yu R
Nat Biotechnol; 2006 May; 24(5):509-15. PubMed ID: 16680129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
